Moraski, G., Garrett, C., Lowell, M., Jeffrey, C., Philip, H., Helena, B., Mai, B., Torey, A., Juliane, O., Tanya, P. and Marvin, M. (2013) Advancement of Imidazo[1,2-a]Pyridines with Improved Pharmacokinetics and nM Activity vs. Mycobacterium tuberculosis. ACS Medicinal Chemistry Letters, 4, 675-679.
https://doi.org/10.1021/ml400088y

has been cited by the following article:

• TITLE: Synthesis and Evaluation of Antituberculosis Activity of Substituted 2,7-Dimethylimidazo [1,2-a]Pyridine-3-Carboxamide Derivatives

  AUTHORS: Bhagwat Jadhav, R. Kenny, Y. Nivid, Mustapha Mandewale, Ramesh Yamgar

  KEYWORDS: Carboxamides, Imidazo[1, 2-a]Pyridine, Tuberculosis

  JOURNAL NAME: Open Journal of Medicinal Chemistry, Vol.6 No.4, December 29, 2016

  ABSTRACT: A series of substituted 2,7-dimethylimidazo[1,2-a]pyridine-3-carboxamides derivatives 5a-5m were synthesized through multi-step reactions. To achieve the synthesis of the desired compounds monobromo and dibromo substituted 2-amino-γ-picoline was reacted with ethyl 2-chloroacetoacetate. The crude ethyl ester subjected to hydrolysis in presence of lithium hydroxide to get 2a and 2b, with imidazo[1,2-a]pyri- dine-3-carboxylic acid to get 3a-3b, on treatment with substituted amines 4a-4g to get desired product 5a-5m in presence of EDCI and HOBt. The substituted imidazo[1,2-a]pyridine-3-carboxamides are characterized by FTIR, 1H-NMR, 13C-NMR and mass spectra. These newly synthesized compounds were tested in vitro for their antimycobacterial activity. The preliminary results of antituberculosis study showed that most of the synthesized compounds 5a-5m demonstrated moderate to good antituberculosis activity. Among the tested compounds 5b, 5d and 5e were found to be the most active with minimum inhibitory concentration (MIC) of 12.5 μg/mL against Mycobacterium tuberculosis (H37 RV strain) ATCC No-27294.